 Katherine Hisert
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 18 | 2025 | 1166 | 3.080 |
Why?
| | Quinolones | 5 | 2025 | 202 | 1.780 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 8 | 2025 | 371 | 1.510 |
Why?
| | Mycobacterium Infections, Nontuberculous | 5 | 2024 | 368 | 1.470 |
Why?
| | Aminophenols | 6 | 2025 | 202 | 1.460 |
Why?
| | Mycobacterium abscessus | 2 | 2023 | 118 | 0.850 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 161 | 0.760 |
Why?
| | Bronchiectasis | 1 | 2024 | 112 | 0.750 |
Why?
| | Sputum | 5 | 2021 | 308 | 0.720 |
Why?
| | Macrophages | 6 | 2024 | 1496 | 0.690 |
Why?
| | Lung | 10 | 2023 | 4089 | 0.560 |
Why?
| | Cell Separation | 1 | 2019 | 303 | 0.550 |
Why?
| | Respiratory Tract Infections | 2 | 2021 | 395 | 0.500 |
Why?
| | Nontuberculous Mycobacteria | 4 | 2024 | 210 | 0.480 |
Why?
| | Pseudomonas Infections | 4 | 2021 | 230 | 0.470 |
Why?
| | Flow Cytometry | 1 | 2019 | 1154 | 0.450 |
Why?
| | Pseudomonas aeruginosa | 4 | 2021 | 391 | 0.440 |
Why?
| | Proteome | 2 | 2019 | 515 | 0.440 |
Why?
| | Inflammation | 6 | 2024 | 2870 | 0.420 |
Why?
| | Mycobacterium tuberculosis | 3 | 2022 | 337 | 0.370 |
Why?
| | Benzodioxoles | 2 | 2025 | 159 | 0.370 |
Why?
| | Chloride Channel Agonists | 3 | 2025 | 109 | 0.360 |
Why?
| | Bacterial Proteins | 3 | 2019 | 981 | 0.290 |
Why?
| | Mutation | 3 | 2023 | 4081 | 0.270 |
Why?
| | Interferon-gamma | 2 | 2011 | 781 | 0.230 |
Why?
| | Cyclic GMP | 1 | 2005 | 90 | 0.220 |
Why?
| | Diphenylamine | 1 | 2024 | 8 | 0.210 |
Why?
| | Phagocytosis | 2 | 2023 | 296 | 0.200 |
Why?
| | Zymosan | 1 | 2023 | 39 | 0.200 |
Why?
| | Salmonella typhimurium | 1 | 2005 | 189 | 0.200 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2004 | 131 | 0.200 |
Why?
| | Humans | 21 | 2025 | 144667 | 0.190 |
Why?
| | Respiratory Mucosa | 1 | 2025 | 322 | 0.190 |
Why?
| | Benzamides | 1 | 2024 | 224 | 0.190 |
Why?
| | Indoles | 1 | 2025 | 504 | 0.170 |
Why?
| | Fibrosis | 1 | 2024 | 547 | 0.170 |
Why?
| | Pyridines | 1 | 2025 | 603 | 0.170 |
Why?
| | Recombinant Proteins | 1 | 2024 | 1363 | 0.160 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 248 | 0.160 |
Why?
| | Polysaccharides, Bacterial | 1 | 2021 | 69 | 0.160 |
Why?
| | Bacteriophages | 1 | 2022 | 111 | 0.160 |
Why?
| | Mucus | 1 | 2020 | 74 | 0.160 |
Why?
| | Animals | 9 | 2024 | 37948 | 0.150 |
Why?
| | Stem Cells | 1 | 2023 | 621 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 1036 | 0.140 |
Why?
| | Anti-Bacterial Agents | 6 | 2022 | 1928 | 0.140 |
Why?
| | Toll-Like Receptors | 1 | 2019 | 193 | 0.140 |
Why?
| | Pilot Projects | 1 | 2024 | 1886 | 0.140 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 541 | 0.130 |
Why?
| | Mice | 7 | 2024 | 18261 | 0.130 |
Why?
| | Inovirus | 1 | 2016 | 2 | 0.130 |
Why?
| | DNA Transposable Elements | 3 | 2011 | 125 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 944 | 0.120 |
Why?
| | Monocytes | 2 | 2016 | 536 | 0.120 |
Why?
| | Cell Survival | 1 | 2019 | 1092 | 0.120 |
Why?
| | Infection Control | 1 | 2015 | 174 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2019 | 843 | 0.100 |
Why?
| | Neutrophils | 1 | 2019 | 1118 | 0.100 |
Why?
| | Cross Infection | 1 | 2015 | 263 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1766 | 0.090 |
Why?
| | Disease Outbreaks | 1 | 2015 | 423 | 0.090 |
Why?
| | Adult | 7 | 2025 | 40489 | 0.090 |
Why?
| | Rats | 1 | 2020 | 5570 | 0.090 |
Why?
| | Polyketide Synthases | 1 | 2011 | 7 | 0.090 |
Why?
| | Mupirocin | 1 | 2010 | 7 | 0.080 |
Why?
| | Apoptosis | 1 | 2019 | 2397 | 0.080 |
Why?
| | Staphylococcal Skin Infections | 1 | 2010 | 40 | 0.080 |
Why?
| | Genetic Variation | 1 | 2015 | 985 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3183 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2014 | 643 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 130 | 0.080 |
Why?
| | Nitric Oxide Synthase | 2 | 2011 | 234 | 0.070 |
Why?
| | Male | 10 | 2025 | 72431 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2754 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2015 | 2909 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 5967 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2010 | 454 | 0.060 |
Why?
| | Biofilms | 2 | 2021 | 301 | 0.060 |
Why?
| | Lipids | 1 | 2011 | 706 | 0.060 |
Why?
| | Airway Remodeling | 1 | 2025 | 63 | 0.060 |
Why?
| | Mutagenesis, Insertional | 1 | 2005 | 68 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2025 | 123 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2005 | 371 | 0.050 |
Why?
| | Drug Combinations | 1 | 2025 | 393 | 0.050 |
Why?
| | Quinolines | 1 | 2025 | 192 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2004 | 161 | 0.050 |
Why?
| | Female | 7 | 2025 | 78304 | 0.050 |
Why?
| | Patient Acuity | 1 | 2024 | 47 | 0.050 |
Why?
| | Mutagenesis | 1 | 2004 | 194 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2005 | 334 | 0.050 |
Why?
| | Mammals | 1 | 2024 | 296 | 0.040 |
Why?
| | Pyrazoles | 1 | 2025 | 512 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2136 | 0.040 |
Why?
| | Expectorants | 1 | 2021 | 23 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3147 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2022 | 420 | 0.040 |
Why?
| | Armadillo Domain Proteins | 1 | 2019 | 6 | 0.040 |
Why?
| | Glyoxylates | 1 | 2019 | 8 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2021 | 205 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 347 | 0.040 |
Why?
| | Escherichia coli | 1 | 2024 | 854 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 155 | 0.040 |
Why?
| | Carbon | 1 | 2019 | 203 | 0.030 |
Why?
| | Lactic Acid | 1 | 2019 | 303 | 0.030 |
Why?
| | Down-Regulation | 1 | 2019 | 616 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 435 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 454 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11735 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2847 | 0.030 |
Why?
| | Palmitates | 1 | 2014 | 21 | 0.030 |
Why?
| | Mice, Obese | 1 | 2014 | 66 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 14122 | 0.030 |
Why?
| | Culture Media, Conditioned | 1 | 2014 | 111 | 0.030 |
Why?
| | Antigens, Surface | 1 | 2014 | 155 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 177 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1159 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 828 | 0.020 |
Why?
| | Autophagy | 1 | 2014 | 284 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 426 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4261 | 0.020 |
Why?
| | Cell Wall | 1 | 2011 | 59 | 0.020 |
Why?
| | Methicillin Resistance | 1 | 2010 | 17 | 0.020 |
Why?
| | Ointments | 1 | 2010 | 25 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2014 | 524 | 0.020 |
Why?
| | Cell Membrane | 1 | 2014 | 706 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2010 | 93 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 242 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 303 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2011 | 169 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 1033 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4110 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2350 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 2033 | 0.010 |
Why?
| | Insulin | 1 | 2014 | 2502 | 0.010 |
Why?
| | United States | 1 | 2019 | 16018 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 35971 | 0.010 |
Why?
|
|
Hisert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|